Since the development and application of anti-TNF-α, a variety of monoclonal antibodies have been continuously developed and applied to enrich the precision targeted therapy for IBD.As first-line agents for the treatment of IBD, anti-TNF-α monoclonal antibodies such as infliximab and adalimumab have long been utilized to mitigate inflammation and promote mucosal healing (56). Here, TNF is linked to inflammatory bowel disease.